Mixed Study Results in GU Tumor Types Reported From 2015 ECC
Renal Cell Carcinoma Vaccine Fails to Improve Outcomes
The IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.
In Kidney Cancer, Better Outcomes Demonstrated With Nephron-sparing Surgery
Patients with renal cell carcinoma have better outcomes when undergoing nephron-sparing surgery rather than radical nephrectomy.
Tasquinimod Discontinuation in mCRPC Discussed at 2015 ECC
Tasquinimod, a drug that showed great promise in phase II trials, failed to improve overall survival in a phase III trial in men with treatment-naÃ¯ve metastatic castration-resistant prostate cancer.
One Clinic's Multidisciplinary Approach Optimizes the Use of Radium-223
With the advancement of radium-223 comes questions and controversy regarding optimal treatment sequencing, combination therapy, and appropriate patient selection.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.